To the Editor.—
Chlorambucil is an oral nitrogen mustard derivative used primarily to treat chronic lymphocytic leukemia, non-Hodgkin's lymphomas, certain carcinomas,1 and connective tissue diseases.2 The major side effects are dose-related bone marrow depression and gastrointestinal tract symptoms such as anorexia, nausea, and vomiting.3 There are several reports of a possible teratogenic effect and neurotoxic manifestations including convulsions and coma.1 In addition, continuous chlorambucil therapy has been shown to induce neoplasia as a result of cumulative chromosomal damage.2 Allergic skin reactions to chlorambucil therapy are rare. Two cases of chlorambucil-related skin reactions have been reported in patients with chronic lymphocytic leukemia.1,3 We describe a patient with nodular histiocytic lymphoma who had a similar type of skin reaction secondary to chlorambucil therapy.
Report of a Case.—
A previously healthy 61-year-old woman was diagnosed to have stage IV, poorly differentiated, nodular, histiocytic lymphoma in July 1984.
Peterman A, Braunstein B. Cutaneous Reaction to Chlorambucil Therapy. Arch Dermatol. 1986;122(12):1358–1360. doi:10.1001/archderm.1986.01660240020006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: